id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-5256-0008,FDA,FDA-2019-E-5256,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-01-16T05:00:00Z,2025,1,2025-01-16T05:00:00Z,,2025-01-16T21:24:13Z,,0,0,09000064868c4b47
FDA-2019-E-5256-0006,FDA,FDA-2019-E-5256,"Letter from U.S. Patent and Trademark Office to McCarter & English, LLP",Other,Letter(s),2024-02-28T05:00:00Z,2024,2,2024-02-28T05:00:00Z,,2024-02-28T14:38:01Z,,0,0,090000648640d9ff
FDA-2019-E-5256-0007,FDA,FDA-2019-E-5256,Amended Request for Extension of Patent Term,Other,Amendment,2024-02-28T05:00:00Z,2024,2,2024-02-28T05:00:00Z,,2024-02-28T14:38:09Z,,0,0,090000648640dc71
FDA-2019-E-5256-0005,FDA,FDA-2019-E-5256,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T13:26:57Z,,0,0,090000648636562d
FDA-2019-E-5256-0004,FDA,FDA-2019-E-5256,Determination of Regulatory Review Period for Purposes of Patent Extension; SEYSARA,Notice,Determinations,2023-12-08T05:00:00Z,2023,12,2023-12-08T05:00:00Z,2024-02-07T04:59:59Z,2023-12-08T14:19:46Z,2023-27003,0,0,09000064863165a2
FDA-2019-E-5256-0003,FDA,FDA-2019-E-5256,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-12-23T05:00:00Z,2019,12,2019-12-23T05:00:00Z,,2019-12-23T18:47:26Z,,0,0,090000648424ae9f
FDA-2019-E-5256-0002,FDA,FDA-2019-E-5256,"Patent Term Extension Application from Paratek Pharmaceuticals, Inc",Other,Application,2019-11-07T05:00:00Z,2019,11,2019-11-07T05:00:00Z,,2019-11-07T15:34:43Z,,0,0,0900006484128446
FDA-2019-E-5256-0001,FDA,FDA-2019-E-5256,Letter from U S Patent and Trademark Office,Other,Letter(s),2019-11-07T05:00:00Z,2019,11,2019-11-07T05:00:00Z,,2019-11-07T15:25:22Z,,0,0,0900006484128445